William T. Beck

Effects of indole alkaloids on multidrug resistance and labeling of P-glycoprotein by a photoaffinity analog of vinblastine.

W. T. Beck, A. Safa, R. L. Felsted, 1988, Biochemical and biophysical research communications.

Selection of human leukemic CEM cells for resistance to the DNA topoisomerase II catalytic inhibitor ICRF-187 results in increased levels of topoisomerase IIalpha and altered G(2)/M checkpoint and apoptotic responses.

S. Raimondi, W. T. Beck, S. E. Morgan, 2000, Molecular pharmacology.

Altered catalytic activity of and DNA cleavage by DNA topoisomerase II from human leukemic cells selected for resistance to VM-26.

D. Suttle, W. T. Beck, M. Danks, 1988, Biochemistry.

Expression of a mutant DNA topoisomerase II in CCRF-CEM human leukemic cells selected for resistance to teniposide.

D. Suttle, W. T. Beck, M. Danks, 1991, Proceedings of the National Academy of Sciences of the United States of America.

Pharmacological, molecular, and cytogenetic analysis of "atypical" multidrug-resistant human leukemic cells.

J. Trent, D. Suttle, W. T. Beck, 1987, Cancer research.

Altered DNA topoisomerase II in multidrug resistance

D. Suttle, W. T. Beck, Mei Chen, 2004, Cytotechnology.

Differences between drug-sensitive and -resistant human leukemic CEM cells in c-jun expression, AP-1 DNA-binding activity, and formation of Jun/Fos family dimers, and their association with internucleosomal DNA ladders after treatment with VM-26.

W. T. Beck, R. Kim, William T. Beck, 1994, Cancer research.

Comparison of ion channels in multidrug-resistant and -sensitive human leukemic cells.

William T. Beck, Carol Deutsch, Sherwin C. Lee, 1988, Proceedings of the National Academy of Sciences of the United States of America.